Cost minimization and budget impact analysis of rituximab versus infliximab, adalimumab, etanercept and abatacept in rheumatoid arthritis from a payer perspective in Brazil

被引：0
|
作者：
Saggia, M. G. [1 ]
Santos, E. A. [1 ]
Nasciben, V [1 ]
机构：
[1] Roche Brazil, Sao Paulo, Brazil
来源：
VALUE IN HEALTH | 2008年 / 11卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)70821-4
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A260 / A260
页数：1
相关论文
共 50 条
  • [31] Clinical impact of switching from infliximab to etanercept in patients with rheumatoid arthritis
    Laas, Karin
    Peltomaa, Ritva
    Kautiainen, Hannu
    Leirisalo-Repo, Marjatta
    CLINICAL RHEUMATOLOGY, 2008, 27 (07) : 927 - 932
  • [32] Clinical impact of switching from infliximab to etanercept in patients with rheumatoid arthritis
    Karin Laas
    Ritva Peltomaa
    Hannu Kautiainen
    Marjatta Leirisalo-Repo
    Clinical Rheumatology, 2008, 27 : 927 - 932
  • [33] COMPARISON OF COST- EFFICACY OF SUBCUTANEOUS ABATACEPT VERSUS ADALIMUMAB IN THE TREATMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS
    Khanna, D.
    Massarotti, E.
    Rosenblatt, L.
    Budd, D.
    Sabater, J.
    Hebden, T.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 340 - 341
  • [34] COST-PER-RESPONSE ANALYSIS OF SUBCUTANEOUS ABATACEPT VERSUS ADALIMUMAB FOR THE TREATMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS - BRAZILIAN PRIVATE HEALTHCARE SYSTEM PERSPECTIVE
    Alves, Nathalie
    Marinheiro, Paola
    Bemardino, Graziela
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2019, 25 : S41 - S41
  • [35] COST-CONSEQUENCE ANALYSIS OF SUBCUTANEOUS ABATACEPT VERSUS ADALIMUMAB IN SEROPOSITIVE, EROSIVE EARLY RHEUMATOID ARTHRITIS - BRAZILIAN PRIVATE HEALTHCARE SYSTEM PERSPECTIVE
    Marinheiro, P.
    Faustino, P.
    Watanabe, S.
    Lima, P.
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2020, 26 : 136 - 136
  • [36] BUDGET-IMPACT ANALYSIS (BIA) OF OBESITY FROM A HEALTHCARE PAYER PERSPECTIVE IN BRAZIL
    Busch, J.
    Reis Neto, J. P.
    VALUE IN HEALTH, 2019, 22 : S595 - S595
  • [37] BUDGET IMPACT ANALYSIS OF TOCILIZUMAB UNDER THE PUBLIC PAYER PERSPECTIVE IN BRAZIL
    Saggia, M. G.
    Santos, E. A.
    VALUE IN HEALTH, 2009, 12 (07) : A436 - A437
  • [38] BUDGET IMPACT ANALYSIS OF AN ETANERCEPT BIOSIMILAR FOR THE TREATMENT OF RHEUMATOID ARTHRITIS IN EUROPE
    Ruff, L.
    Rezk, M. F.
    Uhlig, T.
    Gommers, J. W.
    VALUE IN HEALTH, 2015, 18 (07) : A639 - A639
  • [39] Cost-effectiveness analysis of etanercept monotherapy versus infliximab plus methotrexate in the treatment of rheumatoid arthritis.
    Malone, DC
    ARTHRITIS AND RHEUMATISM, 2001, 44 (09): : S322 - S322
  • [40] COMPARING ABATACEPT TO ADALIMUMAB, ETANERCEPT AND INFLIXIMAB AS FIRST OR SECOND LINE AGENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS. EXPERIENCE FROM THE RHUMADATA® CLINICAL DATABASE AND REGISTRY
    Fortin, I.
    Choquette, D.
    Bessette, L.
    Haraoui, B.
    Pelletier, J. -P.
    Raynauld, J. P.
    Remillard, M-A
    Sauvageau, D.
    Villeneuve, E.
    Coupal, L.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 273 - 274
12345